Researcher Spotlight: Ruth Alonso-Alonso, PhD THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Oliver W. Press, MD, PhD Memorial Fellow Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of peripheral T-cell lymphoma. Therapeutic options for AITL are…
Researcher Spotlight: Samuel Yamshon, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The lymphoma treatment landscape has been dramatically changed in recent years with the development of novel immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies. Dr.…
Researcher Spotlight: Yucai Wang, MD MAYO CLINIC ROCHESTER Dr. Wang’s interest in cancer research began during his time in medical school at Nanjing University in China. He had lost two close family members to lymphoma and was drawn to pursue…
Researcher Spotlight: Timothy Vorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Post-transplant lymphoproliferative disorders (PTLDs) are aggressive forms of lymphoma that develop after a solid organ transplant, often due to reactivation of the Epstein-Barr virus (EBV) following the use…
Researcher Spotlight: Harsh Shah, DO The University of Utah Immunotherapy with checkpoint inhibitors is commonly used for treatment of Hodgkin lymphoma after relapse. While many patients initially respond to these therapies, the development of resistance is common over time. Dr.…
Researcher Spotlight: Christine Ryan, MD Dana-Farber Cancer Institute Upfront treatment of mantle cell lymphoma (MCL) typically involves an aggressive approach to treatment that offers the best chance of a durable and lasting response. Dr. Ryan is investigating a new first-line…
Researcher Spotlight: Niloufer Khan, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Health Equity Initiative Cutaneous T-cell lymphoma (CTCL) is a chronic form of cancer that causes pain, discomfort, and itchiness that can affect patients’ well-being and quality of life. “Itch…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Tomohiro Aoki, MD, PhD UNIVERSITY HEALTH NETWORK Peykoff Initiative Investigator Cancer cells exist within a greater tumor microenvironment that is modified by tumor cells to support their growth and proliferation. These cells can also modify their environment to…